PFM Health Sciences, LP
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ASCENDIS PHARMA A/S | ASND | $62.2M | 233,171 | - | new | NEW | |
| AXSOME THERAPEUTICS INC | AXSM | $53.8M | 219,596 | +0.54pp | 17q | -16.9%-$10.9M | |
| ELI LILLY & CO | LLY | $47.1M | 39,258 | -1.47pp | 23q | -40.3%-$31.8M | |
| JAZZ PHARMACEUTICALS PLC | JAZZ | $38.7M | 160,768 | +0.25pp | 3q | -9.8%-$4.2M | |
| HUMANA INC | HUM | $37.5M | 94,375 | - | new | NEW | |
| UNITEDHEALTH GROUP INC | UNH | $36.7M | 88,276 | +1.72pp | 3q | +52.1%+$12.6M | |
| NEUROCRINE BIOSCIENCES INC | NBIX | $36.0M | 213,407 | +0.50pp | 5q | -1.1%-$382.7K | |
| INHIBRX BIOSCIENCES INC | INBX | $29.2M | 308,385 | +0.63pp | 9q | +1.0%+$279.9K | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $27.1M | 49,991 | -4.02pp | 5q | +25.6%+$5.5M | |
| REVOLUTION MEDICINES INC | RVMD | $26.8M | 143,222 | +1.05pp | 4q | +1.7%+$459.2K | |
| ICON PUB LTD CO | ICLR | $23.7M | 136,482 | +1.45pp | 29q | +137.4%+$13.7M | |
| TENET HEALTHCARE CORP | THC | $23.7M | 126,572 | -4.83pp | 25q | -68.2%-$50.9M | |
| EDWARDS LIFESCIENCES CORP | EW | $22.7M | 250,453 | +0.09pp | 31q | -1.6%-$367.0K | |
| WATERS CORP | WAT | $22.4M | 59,825 | +0.85pp | 10q | +50.5%+$7.5M | |
| CENTENE CORP DEL OPT | CNC | $21.6M | 248,867 | +1.07pp | 4q | -5.5%-$1.3M | |
| PENUMBRA INC | PEN | $19.0M | 60,221 | -2.55pp | 31q | -56.9%-$25.1M | |
| BRIDGEBIO PHARMA INC | BBIO | $18.9M | 253,358 | -0.13pp | 7q | -1.7%-$326.9K | |
| STRYKER CORPORATION | SYK | $17.8M | 56,637 | +0.87pp | 3q | +157.9%+$10.9M | |
| METTLER TOLEDO INTERNATIONAL | MTD | $17.0M | 13,344 | - | new | NEW | |
| INDIVIOR PHARMACEUTICALS INC | INDV | $16.5M | 401,208 | -0.18pp | 2q | -30.2%-$7.1M | |
| MERCK & CO INC | MRK | $16.3M | 127,118 | - | new | NEW | |
| CYTOKINETICS INC | CYTK | $16.3M | 191,686 | - | new | NEW | |
| LANTHEUS HLDGS INC | LNTH | $16.2M | 146,403 | - | new | NEW | |
| COOPER COS INC | COO | $15.8M | 220,890 | +0.25pp | 4q | +30.1%+$3.7M | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $15.7M | 29,313 | -0.28pp | 3q | -14.2%-$2.6M | |
| ACADIA HEALTHCARE COMPANY IN | ACHC | $15.5M | 524,934 | +0.09pp | 2q | -9.9%-$1.7M | |
| ORUKA THERAPEUTICS INC | ORKA | $15.1M | 158,825 | +0.52pp | 2q | -8.7%-$1.4M | |
| OSCAR HEALTH INC | OSCR | $14.8M | 519,016 | +0.75pp | 13q | +3.8%+$547.0K | |
| THERMO FISHER SCIENTIFIC INC | TMO | $14.3M | 28,496 | +0.56pp | 4q | +92.1%+$6.9M | |
| CVS HEALTH CORP | CVS | $14.2M | 137,457 | - | new | NEW | |
| MERIT MED SYS INC | MMSI | $13.7M | 197,038 | +0.15pp | 2q | +21.3%+$2.4M | |
| PRAXIS PRECISION MEDICINES I | PRAX | $12.9M | 38,575 | +0.07pp | 11q | +8.9%+$1.1M | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $12.8M | 342,751 | +0.15pp | 3q | +5.5%+$662.1K | |
| NOVO-NORDISK A S | NVO | $12.7M | 265,016 | +0.43pp | 2q | +34.4%+$3.3M | |
| INTEGER HLDGS CORP | ITGR | $11.8M | 126,669 | -0.07pp | 3q | -6.2%-$786.1K | |
| DIANTHUS THERAPEUTICS INC | DNTH | $11.8M | 121,222 | -0.30pp | 4q | -29.6%-$5.0M | |
| DEFINIUM THERAPEUTICS INC | DFTX | $11.7M | 249,020 | +0.65pp | 2q | +21.3%+$2.1M | |
| GILEAD SCIENCES INC | GILD | $11.5M | 90,858 | - | new | NEW | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $11.3M | 101,550 | -0.12pp | 4q | -25.7%-$3.9M | |
| SCHEIN HENRY INC | HSIC | $11.2M | 134,423 | -0.07pp | 2q | -12.2%-$1.6M | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $10.7M | 131,667 | +0.55pp | 2q | +104.8%+$5.5M | |
| TANGO THERAPEUTICS INC | TNGX | $10.2M | 326,047 | +0.10pp | 2q | -19.7%-$2.5M | |
| TELEFLEX INCORPORATED | TFX | $10.1M | 79,708 | - | new | NEW | |
| CENCORA INC OPT | COR | $10.0M | 7,385 | - | new | NEW | |
| VIKING THERAPEUTICS INC | VKTX | $10.0M | 255,330 | +0.07pp | 5q | -3.0%-$303.3K | |
| BRIGHTSPRING HEALTH SVCS INC | BTSG | $9.9M | 141,914 | +0.12pp | 3q | -24.2%-$3.2M | |
| VERA THERAPEUTICS INC | VERA | $9.6M | 224,289 | +0.18pp | 4q | +28.3%+$2.1M | |
| ROIVANT SCIENCES LTD | ROIV | $9.5M | 268,008 | +0.29pp | 2q | +29.2%+$2.1M | |
| CG ONCOLOGY INC | CGON | $9.1M | 128,286 | -0.24pp | 4q | -22.7%-$2.7M | |
| AMNEAL PHARMACEUTICALS INC | AMRX | $8.3M | 480,715 | -0.34pp | 4q | -48.3%-$7.8M | |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | $8.0M | 1,210,661 | +0.33pp | 2q | +123.8%+$4.4M | |
| IRHYTHM HOLDINGS INC | IRTC | $7.8M | 65,196 | - | new | NEW | |
| KODIAK SCIENCES INC | KOD | $7.5M | 193,315 | +0.25pp | 2q | +68.5%+$3.1M | |
| ABBOTT LABORATORIES | ABT | $7.5M | 82,230 | -0.67pp | 2q | -41.4%-$5.3M | |
| WEST PHARMACEUTICAL SVSC INC | WST | $7.4M | 20,733 | - | new | NEW | |
| TAKEDA PHARMACEUTICAL CO LTD | TAK | $7.1M | 444,173 | - | new | NEW | |
| HINGE HEALTH INC | HNGE | $6.9M | 82,860 | - | new | NEW | |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | $6.3M | 242,069 | - | new | NEW | |
| INTEGRA LIFESCIENCES HLDGS C | IART | $6.3M | 348,746 | - | new | NEW | |
| ILLUMINA INC | ILMN | $6.2M | 35,040 | +0.20pp | 2q | +21.4%+$1.1M | |
| MEIRAGTX HLDGS PLC | MGTX | $6.2M | 455,286 | - | new | NEW | |
| OCULIS HOLDING AG | OCS | $6.0M | 436,042 | - | new | NEW | |
| NATERA INC | NTRA | $6.0M | 22,077 | -0.58pp | 2q | -63.2%-$10.3M | |
| ABIVAX SA | ABVX | $5.8M | 43,264 | +0.22pp | 3q | +62.3%+$2.2M | |
| GUARDANT HEALTH INC | GH | $5.5M | 36,701 | - | new | NEW | |
| CELCUITY INC | CELC | $5.5M | 52,155 | - | new | NEW | |
| BELITE BIO INC | BLTE | $5.4M | 34,803 | -0.40pp | 3q | -41.4%-$3.8M | |
| STRUCTURE THERAPEUTICS INC | GPCR | $4.9M | 91,550 | -0.13pp | 6q | -27.6%-$1.9M | |
| ARCUS BIOSCIENCES INC | RCUS | $4.7M | 152,129 | - | new | NEW | |
| CHARLES RIV LABS INTL INC | CRL | $4.3M | 18,747 | - | new | NEW | |
| ELANCO ANIMAL HEALTH INC | ELAN | $4.2M | 172,489 | - | new | NEW | |
| ARGENX SE | ARGX | $4.2M | 4,482 | +0.05pp | 17q | -1.2%-$49.2K | |
| BIO RAD LABS INC | BIO | $4.1M | 13,995 | - | new | NEW | |
| SPYRE THERAPEUTICS INC | SYRE | $4.1M | 46,217 | - | new | NEW | |
| MBX BIOSCIENCES INC | MBX | $3.9M | 70,971 | +0.14pp | 4q | -1.3%-$50.9K | |
| MIRUM PHARMACEUTICALS INC | MIRM | $3.7M | 31,536 | - | new | NEW | |
| CULLINAN THERAPEUTICS INC | CGEM | $3.5M | 192,442 | +0.01pp | 3q | -15.4%-$636.7K | |
| COMPASS PATHWAYS PLC | CMPS | $3.5M | 247,589 | -0.39pp | 17q | -81.9%-$15.8M | |
| HCA HEALTHCARE INC | HCA | $3.2M | 8,295 | -0.50pp | 16q | -37.9%-$2.0M | |
| CAPRICOR THERAPEUTICS INC | CAPR | $2.9M | 122,221 | -0.09pp | 2q | -1.3%-$38.8K | |
| DENALI THERAPEUTICS INC | DNLI | $2.6M | 100,966 | - | new | NEW | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $2.6M | 118,422 | -0.30pp | 4q | -51.7%-$2.8M | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $2.6M | 143,700 | +0.04pp | 6q | -1.1%-$28.3K | |
| TARSUS PHARMACEUTICALS INC | TARS | $2.6M | 40,579 | -0.29pp | 3q | -49.4%-$2.5M | |
| OUTSET MED INC | OM | $2.5M | 582,122 | +0.01pp | 6q | -2.1%-$54.0K | |
| OMADA HEALTH INC | OMDA | $2.5M | 114,442 | - | new | NEW | |
| ERASCA INC | ERAS | $2.5M | 134,088 | - | new | NEW | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $2.1M | 207,357 | - | new | NEW | |
| OMNICELL COM | OMCL | $2.0M | 49,040 | - | new | NEW | |
| CVRX INC | CVRX | $1.9M | 369,572 | - | new | NEW | |
| HIMS & HERS HEALTH INC | HIMS | $1.7M | 49,454 | - | new | NEW | |
| MINERALYS THERAPEUTICS INC | MLYS | $1.7M | 62,418 | -0.21pp | 3q | -56.3%-$2.2M | |
| TECTONIC THERAPEUTIC INC | TECX | $1.6M | 45,631 | flat | 3q | -1.1%-$17.1K | |
| UNIQURE NV | QURE | $1.2M | 26,396 | +0.04pp | 10q | -38.1%-$748.0K | |
| REZOLUTE INC | RZLT | $661.9K | 127,289 | +0.02pp | 5q | -1.1%-$7.5K | |
| CARIBOU BIOSCIENCES INC | CRBU | $624.2K | 354,687 | -0.11pp | 20q | -63.0%-$1.1M |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $785.8M | 67.4% |
| Medical Devices | $136.8M | 11.7% |
| Insurance | $110.6M | 9.5% |
| Healthcare Services | $87.7M | 7.5% |
| Wholesale & Distribution | $21.3M | 1.8% |
| Other sectors | $23.2M | 2.0% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $1.2B | 96 | 33 | 22 | 41 | 16 | 33.9% | 45 |
| Q1 2026 | $1.1B | 79 | 21 | 34 | 19 | 19 | 44.8% | 45 |
| Q4 2025 | $1.0B | 77 | 30 | 13 | 34 | 23 | 42.8% | 48 |
| Q3 2025 | $1.3B | 70 | 26 | 16 | 24 | 12 | 49.3% | 45 |
| Q2 2025 | $1.2B | 56 | 17 | 13 | 24 | 26 | 53.5% | 45 |
| Q1 2025 | $1.4B | 65 | 11 | 17 | 18 | 24 | 54.4% | 45 |
| Q4 2024 | $1.6B | 78 | 22 | 9 | 26 | 18 | 51.1% | 45 |
| Q3 2024 | $1.8B | 74 | 11 | 14 | 23 | 14 | 49.9% | 45 |
| Q2 2024 | $2.0B | 77 | 9 | 24 | 13 | 16 | 46.4% | 45 |
| Q1 2024 | $2.1B | 84 | 25 | 16 | 16 | 4 | 40.9% | 44 |
| Q4 2023 | $1.7B | 63 | 9 | 15 | 27 | 17 | 45.7% | 45 |
| Q3 2023 | $2.1B | 71 | 7 | 21 | 19 | 16 | 34.8% | 45 |
| Q2 2023 | $2.6B | 80 | 16 | 23 | 16 | 10 | 33.7% | 45 |
| Q1 2023 | $2.3B | 74 | 9 | 22 | 24 | 14 | 38.5% | 45 |
| Q4 2022 | $2.8B | 79 | 14 | 17 | 26 | 16 | 39.4% | 45 |
| Q3 2022 | $2.8B | 81 | 13 | 24 | 13 | 11 | 33.3% | 45 |
| Q2 2022 | $2.6B | 79 | 21 | 21 | 12 | 10 | 34.1% | 46 |
| Q1 2022 | $2.7B | 68 | 10 | 17 | 15 | 13 | 36.1% | 46 |
| Q4 2021 | $2.9B | 71 | 12 | 10 | 23 | 26 | 35.6% | 45 |
| Q3 2021 | $3.4B | 85 | 22 | 13 | 16 | 17 | 33.7% | 46 |
| Q2 2021 | $3.2B | 80 | 14 | 18 | 12 | 14 | 36.5% | 47 |
| Q1 2021 | $3.3B | 80 | 24 | 28 | 22 | 20 | 37.0% | 47 |
| Q4 2020 | $2.8B | 76 | 28 | 18 | 16 | 22 | 35.8% | 50 |
| Q3 2020 | $2.2B | 70 | 22 | 21 | 15 | 23 | 40.6% | 47 |
| Q2 2020 | $1.9B | 71 | 29 | 15 | 21 | 18 | 37.8% | 45 |
| Q1 2020 | $1.2B | 60 | 27 | 14 | 19 | 24 | 37.5% | 45 |
| Q4 2019 | $2.1B | 57 | 20 | 6 | 30 | 35 | 49.2% | 45 |
| Q3 2019 | $3.4B | 72 | 25 | 18 | 27 | 38 | 42.1% | 45 |
| Q2 2019 | $5.3B | 85 | 24 | 31 | 28 | 29 | 40.3% | 45 |
| Q1 2019 | $4.5B | 90 | 36 | 19 | 34 | 40 | 32.7% | 45 |
| Q4 2018 | $3.8B | 94 | 0 | 0 | 0 | 0 | 30.4% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.